Evidence map›Paper›PMID 37903907›Full record

ArticleNature structural & molecular biology2023

The molecular basis of drug selectivity for α5 subunit-containing GABA

Vikram Babu Kasaragod, Tomas Malinauskas, Ayla A Wahid, Judith Lengyel, Frederic Knoflach, Steven W Hardwick, Charlotte F Jones, Wan-Na Chen, Xavier Lucas, Kamel El Omari and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Negative allosteric modulation of α5-GABAbioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Resolving native GABANature · 2025
    Article
  10. Light-Activated Agonist-Potentiator of GABAJournal of the American Chemical Society · 2024
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Vikram Babu KasaragodDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Tomas MalinauskasDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-4847-5529
Ayla A WahidDepartment of Pharmacology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-8128-9632
Judith LengyelRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center, Basel, Switzerland.
Frederic KnoflachRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center, Basel, Switzerland.
Steven W HardwickCryoEM Facility, Department of Biochemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0001-9246-1864
Charlotte F JonesDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Wan-Na ChenDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Xavier LucasRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
Kamel El OmariDiamond Light Source, Harwell Science and Innovation Campus, Didcot, UK.ORCID 0000-0003-3506-6045
Dimitri Y ChirgadzeCryoEM Facility, Department of Biochemistry, University of Cambridge, Cambridge, UK.ORCID 0000-0001-9942-0993
A Radu AricescuMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0003-3783-1388
Giuseppe CecereRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center, Basel, Switzerland.
Maria-Clemencia HernandezRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center, Basel, Switzerland. maria-clemencia.hernandez@roche.com.ORCID 0000-0003-1621-4188
Paul S MillerDepartment of Pharmacology, University of Cambridge, Cambridge, UK. pm676@cam.ac.uk.ORCID 0000-0002-6512-9441
University of Cambridge · GBRoche (Switzerland) · CHMRC Laboratory of Molecular Biology · GBCentre for Human Genetics · GBDiamond Light Source · GB

Funding

Medical Research Council MC_UP_1201/15Wellcome Trust
6 · The paper itself

Abstract

α5 subunit-containing γ-aminobutyric acid type A (GABA

Indexed as

gamma-Aminobutyric AcidReceptors, GABA-AIsoxazolesgamma-Aminobutyric AcidIsoxazolesReceptors, GABA-A

Identifiers

PMID37903907
PMCPMC10716045
OpenAlexW4388020179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.